GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Degree of Financial Leverage

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Degree of Financial Leverage : 0.00 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Frazier Lifesciences Acquisition's Degree of Financial Leverage for the quarter that ended in Sep. 2022 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Frazier Lifesciences Acquisition's Degree of Financial Leverage or its related term are showing as below:

FLAC's Degree of Financial Leverage is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.73
* Ranked among companies with meaningful Degree of Financial Leverage only.

Frazier Lifesciences Acquisition Degree of Financial Leverage Historical Data

The historical data trend for Frazier Lifesciences Acquisition's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition Degree of Financial Leverage Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
Degree of Financial Leverage
- -

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only - - - 0.19 -0.53

Competitive Comparison of Frazier Lifesciences Acquisition's Degree of Financial Leverage

For the Shell Companies subindustry, Frazier Lifesciences Acquisition's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frazier Lifesciences Acquisition's Degree of Financial Leverage Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Frazier Lifesciences Acquisition's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Frazier Lifesciences Acquisition's Degree of Financial Leverage falls into.



Frazier Lifesciences Acquisition Degree of Financial Leverage Calculation

Frazier Lifesciences Acquisition's Degree of Financial Leverage for the quarter that ended in Sep. 2022 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.205 (Sep. 2022) / 0.196 (Sep. 2021) - 1 )/( -5.085 (Sep. 2022) / -1.039 (Sep. 2021) - 1 )
=-2.0459/3.8941
=-0.53***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Frazier Lifesciences Acquisition  (NAS:FLAC) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Frazier Lifesciences Acquisition Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Frazier Lifesciences Acquisition's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830